Full Coverage

Pfizer drops glaucoma drug, NicOx shares slump

earthtimes.org
May 6, 2008
        
Story Timeline:  213 days

PARIS (Reuters) - Pfizer has decided not to take NicOx's experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. ... has decided not to take NicOx's experimental glaucoma... [read full story]                    

Add Comment
Latest article on this story:

NicOx reports encouraging results from Phase IIa glaucoma trial

 pharmaceutical-business-review.com May 8, 2008
First article on this story:

NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing...

 newsblaze.com May 6, 2008
Selected publications with coverage of this story:
redorbit.com pharmaceutical-business-review.com reuters.com indiatimes.com prnewswire.com medicalnewstoday.com earthtimes.org bionity.com newsblaze.com tmcnet.com kirberts.co.uk finanznachrichten.de
RELATED
Found 10 documents:

NicOx reports encouraging results from Phase IIa glaucoma trial

pharmaceutical-business-review.com
May 8, 2008
        

NicOx has reported positive results of a US Phase II study, conducted by its partner Pfizer, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan 0.005% in patients with primary open-angle glaucoma and ocular hypertension.

                   

NicOx Announces U.S. Phase 2a Results For PF-03187207 And Gives An Update On Continuing...

medicalnewstoday.com
May 7, 2008
        

NicOx S.A. (Euronext Paris: COX) announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension.

NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing...

bionity.com
May 6, 2008
        

NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% ... ... NicOx S.A. announced the results of a U.S. phase 2 study,...

Pfizer Pullout Sends NicOx Shares Down

tmcnet.com
May 6, 2008
        

Pfizer Pullout Sends NicOx Shares Down ... Shares of French biotech NicOx SA nosedived Tuesday when partner Pfizer Inc. decided that data from a U.S. Phase II trial in glaucoma and ocular hypertension were not strong enough to warrant an expanded Phase III test. The...

                   

NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing...

finanznachrichten.de
May 6, 2008
        

SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ - NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted ... ... SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the...

Pfizer drops glaucoma drug, NicOx shares slump

indiatimes.com
May 6, 2008
        

Pfizer has decided not to take NicOx's experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. ... The news is a major blow for NicOx, which has been working on...

                   

NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing...

redorbit.com
May 6, 2008
        

www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. ... phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary...

Pfizer drops glaucoma drug, NicOx shares slump

reuters.com
May 6, 2008
        

PARIS (Reuters) - Pfizer has decided not to take NicOx's experimental glaucoma drug PF-03187207 into final Phase III tests after a mid-stage study failed to met its primary endpoint, sending NicOx shares tumbling. ... The news is a major blow for NicOx, which has been...

Nicox says Pfizer not to launch phase 3 study for PF-03187207

finanznachrichten.de
May 6, 2008
        

PARIS (Thomson Financial) - Nicox said Pfizer Inc. has decided not to launch a phase 3 study for the PF-03187207 drug under the companies' joint research ... ... PARIS (Thomson Financial) - Nicox has decided not to launch a phase 3 study for the PF-03187207 drug under the...

                   

NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing...

newsblaze.com
May 6, 2008
        

www.nicox.com ... NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% in patients with primary...

Related categories